Phase II trialA phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy☆
Section snippets
Patients
The research ethics board at the Princess Margaret Hospital approved the clinical trial protocol, and all patients provided written consent before participation. Between December 19, 1997 and August 10, 1999, 140 patients entered the study. Eligibility criteria included clinical T1b-c or T2a-b, NX, M0 (UICC, 1997 [23]) adenocarcinoma of the prostate, Gleason score ≤8, a presenting serum prostate-specific antigen (PSA) ≤20 ng/ml, and an Eastern Cooperative Oncology Group performance status of 0,
Acute and late toxicity
In the first week of RT, no patient had acute GU toxicity and only 1/140 had GI grade 1 toxicity, as assessed by physician. The highest grade of physician-assessed acute toxicity for the 8.5-week course of RT is shown in Table 2. One of the two patients whose treatment was stopped pre-maturely due to grade 3 acute bladder toxicity had been treated previously for in situ bladder transitional cell carcinoma using intravesical bacille Calmette-Guerin (BCG). Table 2 also shows the highest grade of
Acute toxicity
The acute toxicity experienced by the Study Cohort compared favourably with the RTOG 9406 Group 1 (prostate only) dose levels 1 (71.2 Gy) and 2 (76.7 Gy). The vast majority of patients in the Study Cohort experienced little or no acute toxicity, and grade 3 toxicity was rare with our 6-field conformal technique.
Late toxicity
The RTOG scoring system is a well-established method of recording late radiation normal-tissue effects; however, it does not identify chronic rectal bleeding well [2]. The Fox-Chase
Conclusion
Patients treated with 75.6 Gy experienced modest levels of acute and late GI and GU toxicity. Patient and physician-reported late toxicity differ significantly, and future reports should include patient-assessed late toxicity in comparison to baseline patient-assessed function. At a median follow-up of 5 years, the bFFS for this largely intermediate-risk group of patients was 55%. Biopsy results at 3 years post-treatment, with HMWK staining of basal cells, were highly predictive of subsequent
References (31)
Consensus statement: guidelines for PSA following radiation therapy
Int J Radiat Oncol Biol Phys
(1997)- et al.
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
Int J Radiat Oncol Biol Phys
(1995) - et al.
Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients.
Int J Radiat Oncol Biol Phys
(2000) - et al.
Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients
Urology
(1995) - et al.
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial
Lancet
(1999) - et al.
Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer
J Urol
(2002) - et al.
Nerve sparing radical prostatectomy: a different view
J Urol
(1995) - et al.
Dose response in prostate cancer with 8–12 years' follow-up
Int J Radiat Oncol Biol Phys
(2002) - et al.
Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales
Int J Radiat Oncol Biol Phys
(1997) - et al.
Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect
Int J Radiat Oncol Biol Phys
(1996)
Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy
Int J Radiat Oncol Biol Phys
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406
Int J Radiat Oncol Biol Phys
A dose–volume histogram analysis of the seminal vesicles in men treated with conformal radiotherapy to ‘prostate alone’
Clin Oncol (R Coll Radiol)
Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial
Int J Radiat Oncol Biol Phys
Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial
Int J Radiat Oncol Biol Phys
Cited by (0)
- ☆
Meeting Presentation: European Society of Therapeutic Radiology and Oncology, Prague, Czech Republic, September 17–21, 2002. Abstract 357.